hL-FABP Tgマウスの肝障害に対する反応性の検討

宇野 絹子; 美谷島 克宏; 龍 完次朗; 大畑 敬一; 煙山 紀子; 中江 大

doi:10.14869/toxpt.47.1.0_P-78S

The 47th Annual Meeting of the Japanese Society of Toxicology

Session ID : P-78S

DOI https://doi.org/10.14869/toxpt.47.1.0_P-78S

Conference information

Host: The Japanese Society of Toxicology

Name : The 47th Annual Meeting of the Japanese Society of Toxicology

Date : 2020 -

Poster

Investigation of the Responsiveness to Liver Injury in hL-FABP Tg mice

*Kinuko UNO, Katsuhiro MIYAJIMA, Kanjiro RYU, Keiichi OHATA, Noriko KEMURIYAMA, Dai NAKAE

Author information

*Kinuko UNO
Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture
Katsuhiro MIYAJIMA
Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture
Department of Nutritional Science and Food Safety, Graduate School of Agriculture, Tokyo University of Agriculture
Department of Nutritional Science and Food Safety, Faculty of Applied Bioscience, Tokyo University of Agriculture
Kanjiro RYU
Department of Nutritional Science and Food Safety, Graduate School of Agriculture, Tokyo University of Agriculture
Keiichi OHATA
L-FABP Business Department, CMIC Holdings CO., Ltd.
Noriko KEMURIYAMA
Department of Nutritional Science and Food Safety, Faculty of Applied Bioscience, Tokyo University of Agriculture
Dai NAKAE
Department of Food and Nutritional Science, Graduate School of Agriculture, Tokyo University of Agriculture
Department of Nutritional Science and Food Safety, Graduate School of Agriculture, Tokyo University of Agriculture
Department of Nutritional Science and Food Safety, Faculty of Applied Bioscience, Tokyo University of Agriculture

CONFERENCE PROCEEDINGS FREE ACCESS

Details

Abstract

Liver-derived L-FABP is reported to be a potential of disease biomarker for NAFLD/ NASH and viral hepatitis in human patients. CCl4 was administrated subcutaneously once to hL-FABP Tg mice at the dose levels of 2.5, 5 and 10 mL/kg. After 24, 48 and 72 hours of administration, the hepatotoxicity and levels of serum hL-FABP were evaluated. hL-FABP was reached the maximum levels at 24 hours after dosing and then decreased over time with dose-dependently, however, there was no difference in hepatological features at all levels. And the protein expression of hL-FABP in the liver was enhanced over time. The mechanism of these changes will be analyzed.

Corresponding author

Register with J-STAGE for free!